How long does menactra vaccine last

Administer boosters every 5 years thereafter throughout life as long as the person remains at increased risk for meningococcal disease. Both MenB vaccine products require more than 1 dose for maximum protection. Patients must receive the same vaccine product for all doses. For patients at prolonged increased risk for meningococcal disease, CDC recommends MenB booster doses after completion of the primary series. Administer a booster dose of MenB vaccine 1 year after series completion and then every 2 to 3 years thereafter.

Do not predraw vaccine doses. There are no data on the stability of vaccines stored in syringes filled by healthcare professionals. Do not open vaccine vials until time of administration. Providers can also administer meningococcal and other vaccines during the same visit, but at a different injection site, if feasible.

ACA requires coverage of vaccines as indicated on the recommended immunization schedule, including vaccines with shared clinical decision-making recommendations. The Vaccines for Children VFC program also covers vaccines recommended for shared clinical decision-making. What kind of information about MenB vaccine should be considered with a patient when conducting shared clinical decision-making? MenB vaccines were approved based on the serologic response to the vaccine.

No data are available on vaccine effectiveness against clinical disease or duration of protection against clinical disease. Short term protection refers to the known duration of the antibody response. Should college students be vaccinated against meningococcal serogroup B disease?

Several small outbreaks of meningococcal serogroup B disease have occurred on college campuses since Data derived from enhanced CDC meningococcal disease surveillance suggest that college students have 3. However, the recommendation for shared clinical decision-making applies to all college students age 16 through 23 years who may choose to receive MenB vaccine to reduce their risk of meningococcal serogroup B disease. In addition, some colleges and universities require MenB vaccination for incoming students.

What is the schedule for MenB? Healthy adolescents who are not at increased risk for meningococcal B disease should receive 2 doses of Trumenba MenB-FHbp administered at 0 and 6 months.

If the second dose is given at an interval of less than 6 months, a third dose should be given at least 4 months after the 2nd dose. The 3-dose series should be used for all people with functional or anatomic asplenia, people with persistent complement component deficiency an immune system disorder or those who take a complement inhibitor eculizumab [Soliris] or ravulizumab [Ultomiris] , microbiologists who work with meningococcal isolates in a laboratory, and people exposed during serogroup B outbreaks.

Does he need to receive a third dose? If a microbiologist or other person at increased risk has received 2 doses of Trumenba separated by 6 months their vaccine series can be considered to be complete. I have a patient who was given his first dose of Trumenba MenB-FHbp two weeks ago in May, but he just learned that his university requires all students to complete MenB vaccination before arriving on campus in September.

His next dose of Trumenba is due in November. What can we do? The only way to meet the school entry deadline for a complete series by September would be to restart a primary series with Bexsero MenB-4C , which requires two doses spaced at least 4 weeks apart. You must wait a minimum of 4 weeks after the Trumenba dose to initiate the Bexsero series. If a patient received Trumenba meningococcal B vaccine MenB-FHbp 2 months ago and Bexsero meningococcal B vaccine MenB-4C yesterday, should they complete the series with Trumenba or with Bexsero since the two brands are not interchangeable?

What would be the intervals from the Bexsero dose to the subsequent dose s? The patient can complete the series with either vaccine. Can you provide a comprehensive overview of the MenB recommendations? The document is available at www. Are the two MenB vaccines interchangeable? The ACIP meningococcal serogroup B vaccine recommendations state that the same vaccine must be used for all doses in the MenB series, including booster doses.

If the brand of a previous dose is unavailable or cannot be determined, restart the primary series with the available brand. For People with Risk Factors Back to top Do any of the bacterial vaccines that are recommended for people with functional or anatomic asplenia need to be given before splenectomy?

Do the doses count if they are given during the 2 weeks prior to surgery? Doses given during the 2 weeks 14 days before surgery can be counted as valid. If the doses cannot be given prior to the splenectomy, they should be given as soon as the patient's condition has stabilized after surgery.

Our practice has an year-old patient who is having a splenectomy. The doctor requested meningococcal serogroup B vaccine MenB before the surgery and wants to know if the patient will need booster doses or a repeat MenB series at some point in the future as in the meningococcal ACWY vaccine recommendations. Because MenB vaccine brands are not interchangeable, all doses, including booster doses, should be of the same MenB brand.

If the brand of the primary series is not known or not available, CDC recommends restarting the primary series with the available product. I have a patient with paroxysmal nocturnal hemoglobinuria who is being treated with Soliris eculizumab.

Should he receive meningococcal vaccine? Eculizumab Soliris and the related long-acting compound, ravulizumab Ultomiris bind to C5 and inhibit the terminal complement pathway. People with persistent complement component deficiency due to an immune system disorder or use of a complement inhibitor are at increased risk for meningococcal disease even if fully vaccinated.

Because patients treated with complement inhibitors can develop invasive meningococcal disease despite vaccination, clinicians using Soliris or Ultomiris also may consider antimicrobial prophylaxis for the duration of complement inhibitor therapy. We have a year-old getting renal dialysis. The nephrologist will be starting her on ravulizumab Ultomiris , which interferes with C5 complement. A 10 year-old with persistent complement component deficiency also should receive a 2- or 3-dose series depending on brand of MenB vaccine.

As long as the child remains at high risk of meningococcal disease due to complement inhibitor use, booster doses of both MenACWY and MenB are recommended. Are people who are HIV-positive in a risk group for meningococcal disease?

People age 2 years and older with HIV infection who have not been previously vaccinated should receive a 2-dose primary series of MenACWY doses separated by at least 8 weeks. People with HIV infection who have previously received one dose of MenACWY should receive a second dose at the earliest opportunity at least 8 weeks after the previous dose and then receive booster doses at the appropriate intervals. ACIP does not recommend routine meningococcal serogroup B vaccination of people with HIV infection: MenB may be given based upon shared clinical decision-making to people with HIV who are age 16 through 23 years old, preferably between ages 16 and 18 years.

If you choose to give Trumenba brand MenB vaccine MenB-FHbp to a year-old with HIV infection based on shared clinical decision-making, should you use the 2-dose standard schedule or the 3-dose high-risk schedule? If Trumenba is administered, the CDC meningococcal subject matter experts recommend that the 3-dose schedule should be used. People with HIV infection do not appear to be at higher risk for meningococcal serogroup B disease, but because of their HIV infection they might not respond to the vaccine as well, the 3-dose schedule is preferred.

When Bexsero is used, the schedule is 2 doses, regardless of risk status. I have a 7-year-old patient with congenital asplenia. Would you consider giving her meningococcal B vaccine MenB? Use of either brand of MenB in persons younger than age 10 years is off-label in the U.

There is no ACIP recommendation for use of this vaccine for this age group. Food and Drug Administration. It is routinely recommended for infants in the United Kingdom see www. A clinician may choose to use a vaccine off-label if, in their opinion, the benefit of the vaccine exceeds the risk from the vaccine. Are microbiologists recommended to receive MenB vaccine? And if so, how frequently? MenB can be given at the same time as any other vaccine.

MenB vaccine brands work differently and are not interchangeable. All doses, including booster doses, should be of the same brand. If the brand of the primary series is not known or is not available, restart the primary series with the available brand.

We have a year-old patient with a history of vasculitis, nephritis, and asthma. She is on azathioprine Imuran and is immunosuppressed. How often should these vaccines be given? Will she require a series of PCV13 doses or just a booster? MenB is not specifically recommended for immunosuppressed people. However, after discussing the pros and cons of vaccination also known as shared clinical decision-making , people age 16 through 23 years who are not at increased risk may receive routine MenB vaccination with either a 2-dose series of Bexsero MenB-4C 4 weeks apart, or a 2-dose series of Trumenba MenB-FHbp 6 months apart.

As there are generally low numbers of meningococcal disease cases in countries such as Australia, England, Germany, New Zealand and the United States it is not possible to determine exactly how many cases of disease are prevented by vaccination and how long protection after vaccination lasts. Instead, the immune system response and antibody levels are used as an alternative measure of how well and how long meningococcal vaccines can protect from disease. Older children, adolescents and adults are expected to have at least five years protection after immunisation.

Children aged 9—23 months at the time of their last Menactra immunisation are likely to have fewer years of protection but the exact period of time is not known. A booster vaccination should be considered for individuals who remain at increased risk of meningococcal disease:.

Skip to main content. Search form. Clinical queries: Education office: Home Vaccines Available vaccines Menactra Menactra. References Cohn AC, et al. Meningococcal disease quarterly report Jan - Dec Lopez L, Sherwood J. The epidemiology of meningococcal disease in New Zealand Report No. MacNeil et al.

MMRW p New Zealand data sheet: Menactra [Internet]. But some kids and teens who are at increased risk for meningococcal disease should get it starting from age Others who are not at increased risk may also get it between the ages of 16 and 23 preferably between 16 through 18 as that is when the risk of getting infected is highest. The decision to get the MenB vaccine is made by the teen, their parents, and their doctor. When Are Meningococcal Vaccines Given? Vaccination with MenACWY is recommended: when kids are 11 or 12 years old, with a booster given at age 16 for teens 13—18 years old who haven't been vaccinated yet Those who have their first dose between the ages of 13—15 should get a booster dose between the ages of 16— This includes kids who: live in or travel to countries where the disease is common are present during an outbreak of the disease have some kinds of immune disorders.

If the immune disorders are chronic, these kids also need a booster dose a few years later, depending on their age at the first dose. Why Are Meningococcal Vaccines Recommended? When to Delay or Avoid Immunization The vaccine is not recommended if: your child is currently sick. But simple colds or other minor illnesses should not prevent immunization.